Preferred Label : Uliledlimab;
NCIt synonyms : Anti-CD73 Monoclonal Antibody TJ4309;
NCIt definition : A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster
of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating
and antineoplastic activities. Upon administration, uliledlimab targets and binds
to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated
conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing
adenosine-mediated suppression of lymphocyte activity and increasing the activity
of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the
activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes
(Tregs). By abrogating the inhibitory effect on the immune system and enhancing the
CTL-mediated immune response against cancer cells, tumor cell growth is decreased.
CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is
upregulated on a number of cancer cell types and catalyzes the conversion of extracellular
nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it
plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment
(TME).;
UNII : 3OX1DBR75G;
CAS number : 2378407-27-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2378407-27-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : TJD5; TJ 4309; TJ-4309; TJ-004309; TJ 004309;
NCI Metathesaurus CUI : CL951040;
Origin ID : C159168;
UMLS CUI : C5449394;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
